OZEM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

OZ

AUM

N/A

Volume

5.14K

Yield

1.39%

Chart Earnings News About Dividends Insider Filings

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinAt the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.Zacks Investment Research · Oct 1, 2026

Best ETF Areas of Last WeekWall Street was upbeat last week.Zacks Investment Research · Jun 11, 2024

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term PotentialWith more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential. The Roundhill GLP-1 Weight Loss ETF (NASDAQ:OZEM) and the Amplify Weight Loss Drug and Treatment ETF (NYSE:THNR) debuted on May 21 with an expense ratio of 0.59%. Both ETFs have significant weightings in industry giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), with OZEM and THNR allocating about 40% and 30%, respectively, to these companies. Eli Lilly and ...Full story available on Benzinga.comBenzinga · Jun 7, 2024

ETFs to Profit from the Weight Loss Drug BoomThe market for GLP-1 drugs could soar to $130 billion by 2030Zacks Investment Research · Jun 4, 2024

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo NordiskThe recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning weight-loss drug market, making up over 40% of OZEM’s portfolio. This ETF presents a unique opportunity for investors to gain exposure to the weight-loss sector through these dominant players. We covered the ETF’s launch here: EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic Weight-Loss Drug ETFs: A Targeted Investment Weight-loss drug ETFs like OZEM are designed to capitalize on the growing demand for effective weight-management solutions, driven by the increasing prevalence of obesity. The focal point of these ETFs is GLP-1 drugs, a class of medications known for their dual benefits in treating type 2 diabetes ...Full story available on Benzinga.comBenzinga · May 30, 2024

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like OzempicRoundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry. Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such as Eli Lilly & Co. (NYSE:LLY), the producer of Zepbound, and Novo Nordisk A/S (NYSE:NVO), the maker of Ozempic. “These new treatments work incredibly well,” Roundhill CEO Dave Mazza told Benzinga. Citing Goldman Sachs research, Mazza believes the market for weight loss drugs could expand more than 16 times its current size from its current $6 billion and reach $100 billion by 2030. Mazza compared the market dominance of Novo Nordisk and Eli Lilly in the weight loss drug sector to Nvidia Corp.‘s (NASDAQ:NVDA) position in generative AI. Over 40% of the OZEM portfolio is invested in these two weight-loss drug ...Full story available on Benzinga.comBenzinga · May 21, 2024

EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells BenzingaThe return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week. While there are several ETFs that provide exposure to meme stocks, an ETF that previously focused exclusively on meme stocks closed in 2023. Benzinga chatted recently with the CEO of the company behind the MEME ETF. What Happened: ETF company Roundhill Investments was the first to market with several thematic investment vehicles including a sports betting ETF, launched in 2020. In December 2021, Roundhill launched a meme stock ETF aimed at capturing interest in meme stocks, which grew in popularity during the early months of the year. The ETF, which had the appropriate MEME ticker, closed in November 2023. Roundhill Investments CEO Dave Mazza told Benzinga the ETF was closed "due to lack of assets under management and limited trading volume." With meme stocks gaining interest once again, Benzinga reached out to find out what it would take to bring the ETF back. "Time will tell is meme stocks make a meaningful comeback outside of the renewed interest in the last week. The current meme wave remains ...Full story available on Benzinga.comBenzinga · May 17, 2024

OZ

OZEMRoundhill GLP-1 & Weight Loss ETF

OZEM

Pay with—

Available Balance0.00

Your PositionYou don't own any OZEM yet.

Related Tickers

Earnings

Dividends

Last · Dec 30Annual

Amount$0.41

Yield1.39%

Annual$0.41